Global Enteric Disease Testing-Treatment Market – Industry Trends and Forecast to 2029

Market Analysis and Insights Global Enteric Disease Testing-Treatment Market

Data Bridge Market Research analyses that the enteric disease testing-treatment market to growing at a CAGR of 4.30% in the forecast period of 2022-2029. The market is expected to witness rapid expansion in terms of its capitalization as the major market players are focusing on development of products that help physicians and patients in a better healthcare delivery.

Enteric diseases are a type of intestinal disease caused by the presence of various microorganisms such as parasites, viruses, and bacteria. These microorganisms are commonly found in various food products and water bodies, and this disease category is also communicable between individuals. Enteric disease testing and treatment refer to the various diagnostic and therapeutic solutions offered by market participants to reduce or eliminate the impact of enteric diseases on the human body.

In the forecasted period, the increasing number of patients suffering from target diseases will be a significant driver of the growth of the enteric disease testing–treatment market. The availability of higher-quality products based on advanced technologies rather than traditional methods is also driving market growth. Furthermore, increased government intervention to improve people's living standards is expected to have a positive impact on the market. The government is primarily responsible for shifting the trend away from traditional diagnostic methods and toward advanced methods.

The market for enteric disease testing is hampered by high equipment and labour costs, as well as the mandatory requirement for sophisticated laboratory conditions for clinical diagnostics. These difficulties are expected to be overcome in the future as a result of the development of various advanced low-cost technologies such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR).

This enteric disease testing-treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on enteric disease testing-treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Enteric Disease Testing-Treatment Market Scope and Market Size

Enteric disease testing - treatment market is segmented on the basis of disease type, therapeutics, testing technology and end user. Each individual segment’s growth is analysed and these insights are subsequently considered before providing you with the market overview which can help you in understanding and identification of your core applications in the broad market.

• On the basis of disease type, the enteric disease testing - treatment market has been segmented into bacterial enteric diseases, viral enteric diseases and parasitic enteric diseases. Bacterial enteric diseases have been further segmented into C.difficile infection, campylobacteriosis, cholera, E.coli infection, H.pylori infection, salmonellosis and shigellosis. Viral enteric diseases have been sub-segmented into rotavirus infection and norovirus infection. Parasitic enteric diseases have segmented into amebiasis, cryptosporidiosis and giardiasis.
• Based on therapeutics, the enteric disease testing - treatment market has been segmented into campylobacter, cryptosporidium, E-Coli, enteroviruses, RhinoViruses, RotaVirus (REOVIRUS), salmonellosis and shigellosis.
• Enteric disease testing-treatment market has been segmented on the basis of testing technology into molecular diagnostics, monoclonal antibodies, immunoassays, differential light scanning, information technology, artificial intelligence (AI), liposomes, flow cytometry, chromatography, diagnostic imaging, gel microdroplets, others
• Based on end user, the enteric disease testing-treatment market has been segmented into hospitals, diagnostic laboratories and physician offices.

Enteric Disease Testing-Treatment Market Country Level Analysis

The enteric disease testing-treatment market is analysed and market size insights and trends are provided by country, disease type, therapeutics, testing technology and end user as referenced above.

The countries covered in the enteric disease testing-treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific will be the most dominant region for the enteric disease testing-treatment market, with the majority of the population living in urban areas suffering from some form of enteric disease. This population is also migrating to cities, increasing demand for higher-quality healthcare services such as diagnostic products, treatment, and other solutions.

The country section of the enteric disease testing-treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The enteric disease testing-treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for enteric disease testing-treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the enteric disease testing-treatment market. The data is available for historic period 2010 to 2020.

Competitive Landscape and Enteric Disease Testing-Treatment Market Share Analysis

The enteric disease testing-treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to enteric disease testing-treatment market.

Some of the major players operating in the enteric disease testing-treatment market are Abbott, BD, Biomerica, Inc., bioMérieux SA, Bio-Rad Laboratories, Inc., Cepheid, CorisBioconcept SPRL, DIASORIN S.p.A., Meridian Bioscience, Inc., Quest Diagnostics Incorporated, Trinity Biotech Ireland, Thermo Fisher Scientific Inc., Mobidiag Ltd., R-Biopharm, GlaxoSmithKline plc, Bharat Biotech, Sanofi, Janssen Global Services, LLC, Eli Lilly and Company, IDL Biotech AB (publ), Merck & Co., Inc., Novartis AG and Takeda Pharmaceutical Company Limited among others.

SKU-24757